Trifluoroacetic acid → (5R)-2-(5-(1-(aminomethyl)cyclopropyl)-1,3,4-oxadiazol-2-yl)-6-(benzyloxy)-1,6-diaza-bicyclo[3.2.1]octan-7-one
反応式
C(O)(C(F)(F)F)=O.C(OC(=O)[NH:14][CH2:15][C:16]1([C:19]2[O:20][C:21]([CH:24]3[CH2:30][CH2:29][C@@H:28]4[CH2:31][N:25]3[C:26](=[O:40])[N:27]4[O:32][CH2:33][C:34]3[CH:39]=[CH:38][CH:37]=[CH:36][CH:35]=3)=[N:22][N:23]=2)[CH2:18][CH2:17]1)(C)(C)C>C(Cl)Cl>[NH2:14][CH2:15][C:16]1([C:19]2[O:20][C:21]([CH:24]3[CH2:30][CH2:29][C@@H:28]4[CH2:31][N:25]3[C:26](=[O:40])[N:27]4[O:32][CH2:33][C:34]3[CH:39]=[CH:38][CH:37]=[CH:36][CH:35]=3)=[N:22][N:23]=2)[CH2:17][CH2:18]1参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
TFA (30 mL) was added to a 0° C. solution of tert-butyl(1-(5-((5R)-6-(benzyloxy)-7-oxo-1,6-diaza-bicyclo[3.2.1]octan-2-yl)-1,3,4-oxadiazol-2-yl)cyclopropyl)methylcarbamate (8 g, 0.017 mol) in DCM (100 mL). The mixture was allowed to warm to rt and was stirred at rt for 1 h. The mixture was concentrated and the residue was washed with Et2O (50 mL), and then filtrated to afford (5R)-2-(5-(1-(aminomethyl)cyclopropyl)-1,3,4-oxadiazol-2-yl)-6-(benzyloxy)-1,6-diaza-bicyclo[3.2.1]octan-7-one (7 g, 99%), which was used directly in the next step. ESI-MS (EI+, m/z): 370.2 [M+H]+.
後処理
- concentrationThe mixture was concentrated
- washthe residue was washed with Et2O (50 mL)
- filtrationfiltrated
出典と根拠
- ORDレコード
- ord-a09c2273e4d346df95d4177ff2fafec7
- 出典データセット
- uspto-grants-2015_01
- 特許番号
- US08933233B2
反応ノート
読み込み中…